ZA200908303B - A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation - Google Patents

A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation

Info

Publication number
ZA200908303B
ZA200908303B ZA2009/08303A ZA200908303A ZA200908303B ZA 200908303 B ZA200908303 B ZA 200908303B ZA 2009/08303 A ZA2009/08303 A ZA 2009/08303A ZA 200908303 A ZA200908303 A ZA 200908303A ZA 200908303 B ZA200908303 B ZA 200908303B
Authority
ZA
South Africa
Prior art keywords
disorders
treatment
protein aggregation
cyclohexane polyalcohol
polyalcohol formulation
Prior art date
Application number
ZA2009/08303A
Other languages
English (en)
Inventor
Joanne Mclaurin
Antonio Cruz
Original Assignee
Waratah Pharmaceuticals Inc
Joanne Mclaurin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waratah Pharmaceuticals Inc, Joanne Mclaurin filed Critical Waratah Pharmaceuticals Inc
Publication of ZA200908303B publication Critical patent/ZA200908303B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA2009/08303A 2006-03-09 2009-11-24 A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation ZA200908303B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78052606P 2006-03-09 2006-03-09
US81986406P 2006-07-11 2006-07-11
US89766707P 2007-01-26 2007-01-26

Publications (1)

Publication Number Publication Date
ZA200908303B true ZA200908303B (en) 2012-08-29

Family

ID=38474578

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2009/08303A ZA200908303B (en) 2006-03-09 2009-11-24 A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation

Country Status (14)

Country Link
US (1) US20100113613A1 (cg-RX-API-DMAC7.html)
EP (1) EP1996175A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009529502A (cg-RX-API-DMAC7.html)
KR (1) KR20090026247A (cg-RX-API-DMAC7.html)
CN (1) CN103054837A (cg-RX-API-DMAC7.html)
AU (1) AU2007222864A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0708725A2 (cg-RX-API-DMAC7.html)
CA (1) CA2644804A1 (cg-RX-API-DMAC7.html)
EA (1) EA200801967A1 (cg-RX-API-DMAC7.html)
IL (1) IL193970A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008011553A (cg-RX-API-DMAC7.html)
NZ (1) NZ571181A (cg-RX-API-DMAC7.html)
WO (1) WO2007101353A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200908303B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
CA2670405A1 (en) * 2006-11-24 2008-05-29 Waratah Pharmaceuticals Inc. Combination treatments for alzheimer's disease and related neurodegenerative diseases
DE102007030695A1 (de) * 2007-07-01 2009-01-08 Sciconcept Gmbh Co-Kristalle aus Harnstoff mit Amid- und/oder Harnstoffderivaten
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2012173808A1 (en) * 2011-06-03 2012-12-20 Elan Pharmaceuticals, Inc. Scyllo-inositol for the treatment of behavioral and psychiatric disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
US10188757B2 (en) 2013-10-22 2019-01-29 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ， インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
JP2021529771A (ja) 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤
WO2020074944A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
EP4132507A4 (en) 2020-04-06 2024-05-15 The General Hospital Corporation METHODS FOR TREATING CORONAVIRUS-INDUCED INFLAMMATORY CONDITIONS

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4515722A (en) * 1982-03-30 1985-05-07 Merck & Co., Inc. Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents
US4474806A (en) * 1982-05-10 1984-10-02 Merck & Co., Inc. Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents
US4952396A (en) * 1986-11-19 1990-08-28 Linus Pauling Institute Of Science & Medicine Method of using phytic acid for inhibiting tumor growth
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4758430A (en) * 1987-01-21 1988-07-19 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
SE8904355D0 (sv) * 1989-12-21 1989-12-21 Perstorp Ab Medicament
US5217959A (en) * 1990-09-06 1993-06-08 Robert Sabin Method of treating multiple sclerosis with phytic acid
US5112814A (en) * 1990-10-24 1992-05-12 Robert Sabin Method of treatment of Parkinson's disease using phytic acid
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
SE9102068L (sv) * 1991-07-03 1993-01-04 Perstorp Ab Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav
SE469260B (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
NZ314111A (en) * 1992-10-05 1997-08-22 Virginia Tech Intell Prop Preparation of d-chiro-inositol by reducing d-chiro-3-inosose
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
DK0619369T3 (da) * 1993-04-05 2003-10-06 Aveve Nv Phytathydrolyse og enzymsammensætning til hydrolyse af phytat
ES2130440T3 (es) * 1993-08-11 1999-07-01 Hokko Chem Ind Co Proceso para producir d-(quiro)-inositol.
SE502574C2 (sv) * 1994-01-25 1995-11-13 Perstorp Ab En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat
US5858326A (en) * 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6232486B1 (en) * 1996-06-11 2001-05-15 Nutrimed Biotech Molecular probes and modulators for PI-PLC and PI 3-kinase
US5880099A (en) * 1996-09-20 1999-03-09 The Regents Of The University Of California Inositol polyphosphates and methods of using same
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
US6153603A (en) * 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US6818430B1 (en) * 1999-06-07 2004-11-16 Hokko Chemical Industry Co., Ltd. Process for producing L-epi-2-inosose and novel process for producing epi-inositol
US6329256B1 (en) * 1999-09-24 2001-12-11 Advanced Micro Devices, Inc. Self-aligned damascene gate formation with low gate resistance
NZ518685A (en) * 1999-10-18 2004-04-30 Muscletech Res And Dev Inc Whey protein derivatives as food supplements that increase nitric oxide production in the body to enhance muscle size and strength
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
DE10031955A1 (de) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
AU2002236988A1 (en) * 2001-02-06 2002-08-19 Novartis Ag Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration
CA2437561A1 (en) * 2001-02-06 2002-08-15 Qlt Inc. Use of additional photodynamic therapy in the treatment of choroidal neovasculature
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ATE458042T1 (de) * 2003-10-14 2010-03-15 Hokko Chem Ind Co Verfahren zur herstellung von scyllo-inositol
EP2186518A1 (en) * 2004-11-17 2010-05-19 McLaurin, Joanne Composition and methods for treatment of disorders of protein aggregation

Also Published As

Publication number Publication date
AU2007222864A1 (en) 2007-09-13
IL193970A0 (en) 2009-08-03
CN103054837A (zh) 2013-04-24
EA200801967A1 (ru) 2009-04-28
AU2007222864A8 (en) 2010-06-10
WO2007101353A1 (en) 2007-09-13
CA2644804A1 (en) 2007-09-13
BRPI0708725A2 (pt) 2011-06-07
EP1996175A1 (en) 2008-12-03
EP1996175A4 (en) 2009-06-10
US20100113613A1 (en) 2010-05-06
MX2008011553A (es) 2008-12-09
JP2009529502A (ja) 2009-08-20
NZ571181A (en) 2011-12-22
KR20090026247A (ko) 2009-03-12

Similar Documents

Publication Publication Date Title
ZA200908303B (en) A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
EP2010187A4 (en) CONNECTIONS FOR DISEASES AND FUNCTIONAL DISORDERS
ZA200809528B (en) Treatment for depressive disorders
IL213341A0 (en) Dipeptide linked medicinal agents
GB0918546D0 (en) Compounds for treating ophthalmic diseases and disorders
PT2004155T (pt) Inibidores de agregação proteica
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
IL209267A (en) Combinations containing methotrexate and dhodh inhibitors and their use in the preparation of the drug
ZA200809527B (en) Treatment for depressive disorders
IL193747A0 (en) New therapeutic combinations for the treatment of depression
ZA201101278B (en) Compounds,compositions and methods for the treatment of b-amyloid diseases and synucleinopathies
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
PL2341047T3 (pl) Pochodna cykloheksanowa i jej farmaceutyczne zastosowanie
EP1993523A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
GB2458868A8 (en) Treatment of protein aggregation diseases
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
ZA200807993B (en) A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
IL212719A0 (en) Gold nanoparticles coated with polyelectrolytes and use thereof as medicament for the treatment of neurodegenerative diseases caused by protein aggregates
EP2059238A4 (en) THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS
ZA200900556B (en) Use of flumazenil in the manufacture of a medicament for the treatment of depressive disorders
GB0616122D0 (en) Formulation for treatment of skin disorders
HK1144087A (en) Compounds for treating ophthalmic diseases and disorders
HK1160633A (en) Compounds for treating ophthalmic diseases and disorders